tokyo and cambridge, mass., december 13, 2023 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (aβ) monoclonal antibody “leqembi® intravenous infusion” (200 mg, 500mg, lecanemab) will be launched in japan on december 20, following its scheduled inclusion in the price listing on the japan national health insurance (nhi) drug price list.
eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.
eisai has grown smoothly since entering the chinese market in the early 1990s and the total …